A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin by Fan, D, Yang, H, Mao, W, Rask, PJ, Pang, L, Xu, C, Vankayalapat, H, Bast, RC, Ahmed, AA, Lu, Z

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers by Lu, Z, Mao, W, Yang, H, Santiago-O'Farrill, JM, Rask, PJ, Mondal, J, Chen, H, Ivan, C, Liu, X, Liu, C-G, Xi, Y, Masuda, K, Carrami, EM, Chen, M, Tang, Y, Pang, L, Lakomy, DS, Calin, GA, Liang, H, Ahmed, AA, Vankayalapati, H, Bast, RC

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase-2 regulates TP53-dependent paclitaxel sensitivity in ovarian and breast cancers by Yang, H, Zhang, S, Jiang, Y, Mao, W, Pang, L, Redwood, A, Jeter-Jones, SL, Jennings, NB, Ornelas, A, Zhou, J, Rodriguez-Aguayo, C, Bartholomeusz, G, Iles, LR, Zacharias, NM, Millward, SW, Lopez-Berestein, G, Le, X-F, Ahmed, AA, Piwnica-Worms, H, Sood, AK, Bast, RC, Lu, Z